← Back to headlines
Regeneron Stock Slides After Melanoma Study Misses Endpoint
Regeneron Pharmaceuticals saw its stock decline after a melanoma study conducted by the company failed to meet its key endpoint, impacting investor confidence.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
